Latest Biotech News

Eikon Therapeutics filed for a U.S. IPO, positioning the structural biology and drug‑discovery company as an early test of public appetite for biotech in 2026. The filing follows a period of...

Alveus Therapeutics emerged with $160 million in financing to advance a Phase 2‑ready lead program that targets the same dual pathway as Amgen’s MariTide, alongside additional candidates including...

Aragen Biologics launched CHOMax, an integrated CHO cell‑line development and early manufacturing platform designed to move antibody programs from DNA to IND‑enabling supply. The company says...

Cellares signed a collaboration with City of Hope to evaluate its Cell Shuttle manufacturing platform and Cell Q quality‑control automation for City of Hope’s CARpool program targeting...

Aktis Oncology completed its initial public offering, pricing 17.65 million shares at $18 each and raising approximately $318 million in gross proceeds. The upsized offering positions the...

Illumina announced the appointment of Eric Green, former director of the National Human Genome Research Institute, as chief medical officer effective February 2. Green will lead Illumina’s...

Major media reported that Merck & Co. has entered talks to acquire Revolution Medicines in a deal valued between $28 billion and $32 billion. The discussions center on Revolution’s oncology...

Eli Lilly announced a definitive agreement to acquire Ventyx Biosciences for $1.2 billion in cash. Lilly said the deal supplements its inflammation portfolio with Ventyx’s NLRP3 inhibitor assets,...

Scientists behind the ‘Baby KJ’ bespoke CRISPR treatment have launched Aurora Therapeutics with seed backing to develop personalized gene‑editing medicines for ultra‑rare mutations. Menlo Ventures...

Alveus Therapeutics closed a $160 million financing to advance its lead obesity program into Phase 2. The company’s primary candidate targets the same receptor combination as Amgen’s MariTide but...

Venture activity surged as private biotech companies secured roughly $2 billion in a concentrated fundraising week ahead of major industry conferences. Multiple startups closed megaround...

Cellares signed an agreement with City of Hope to evaluate the Cell Shuttle automated manufacturing platform and Cell Q quality control system for City of Hope’s CARpool program — an...

Krystal Biotech disclosed early clinical findings indicating its gene therapy approach can deliver native cystic fibrosis protein across mutation types and produced signals the company views as...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to bridge venture investors and emerging biotech companies, with the stated goal of accelerating capital...

Aktis Oncology priced an upsized initial public offering that raised $318 million, marking biotech’s first major public debut of 2026. The Boston-based radiopharmaceutical developer sold 17.65...

Eli Lilly agreed to acquire Ventyx Biosciences in a cash deal valued at roughly $1.2 billion to add oral NLRP3 inhibitors to its inflammation portfolio. Lilly said the acquisition will broaden its...

Parabilis Medicines closed a $305 million Series F to accelerate zolucatetide and other Helicon‑platform candidates that target intracellular, historically intractable oncology proteins. The...

Boltz PBC spun out of MIT with a $28 million seed round to commercialize a suite of open, AI‑driven drug discovery models developed at CSAIL. Led by co‑founders from Regina Barzilay’s group, the...

Krystal Biotech disclosed early clinical findings for a mutation‑agnostic gene therapy intended to deliver native protein to cystic fibrosis patients, and the company signaled plans to pursue a...

Orca Bio raised $250 million in financing to support the commercial launch of its T‑cell therapy for complications arising after allogeneic stem cell transplant. The round is intended to fund...